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considered adherent users. Bootstrap methods stratified by propensity score were
used to compare adherence and the changes in opioid use 6 months before and
after index date, and regression models were applied to identify factors associated
with change in opioid use. RESULTS: A total of 3033 duloxetine patients and 1065
celecoxib patients were identified. Duloxetine cohort were more likely to adhere to
the treatment than celecoxib cohort (27.4% vs. 15.0%, p0.01). Both cohorts had
significant increases (pre- to post-index) in days on opioids (duloxetine: 3.6, p0.01;
celecoxib: 11.2, p0.01) and morphine equivalent units (duloxetine: 588.8, p0.01;
celecoxib: 587.7, p0.01), whereas only celecoxib cohort had significant increase in
the number of opioid prescriptions (duloxetine: 0.06, p0.44; celecoxib: 0.65,
p0.01). After adjusting for baseline characteristics using bootstrap method, cele-
coxib cohort had significantly greater increase in days on opioids (18.2, p0.01),
morphine equivalent units (1,144, p0.01) and number of opioid prescriptions
(1.24, p0.01) than duloxetine cohort. CONCLUSIONS: Patients who initiated du-
loxetine were more likely to adhere to the initiated treatment than celecoxib initi-
ators, and had significantly less increase in opioid use after initiation.
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OBJECTIVES: In health outcomes research, where researchers from many disci-
plines interact frequently, a tool to communicate treatment patterns clearly and
effectively through graphical means is a necessity. Using data visualization tech-
niques, we aimed to present treatment patterns of rheumatoid arthritis (RA)
patients. METHODS: This study used the Veterans Health Administration (VHA)
Medical SAS® Dataset for patients age 18 with at least two diagnoses for RA 60
days apart during the 1-year baseline period. Patients who initiated therapy with
tumor necrosis factor (TNF) and non-TNF agents were identified. We examined
treatment patterns (switch to another TNF, to a non-TNF, discontinuation) for 2
years after TNF biologic initiation. We created a data visualization tool to represent
changes in treatment patterns after the first and second switches. RESULTS:A total
of 3,205 RA patients initiated therapy with a TNF medication. 12.45% of these pa-
tients switched to another TNF, while 1.65% switched to a non-TNF, 42.12% discon-
tinued therapy and 43.78% continued initial therapy. Among patients who
switched to another TNF, 58.40% continued the switched therapy, 30.08% discon-
tinued, 6.77% switched to another TNF, and 4.76% switched to a non-TNF. Of pa-
tients who first switched to a non-TNF, 67.92% discontinued. The percentages of
those who switched to another anti-TNF and to a non-TNF were both 3.77%. A total
of 412 RA patients initiated therapy with a non-TNF, of which 1.21% switched to
another non-TNF, 3.16% switched to a TNF, 90.29% discontinued, and 5.34% con-
tinued initial therapy. Among those who switched to another TNF, 7.69% switched
to a non-TNF, 30.77% continued, and 46.15% discontinued. All patients who first
switched to another non-TNF discontinued treatment during the second switch
period. CONCLUSIONS: When analyzing subsequent years and switches, treat-
ment patterns can be difficult to capture. Data visualization tools help present
complicated flows effectively for a diverse research audience.
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OBJECTIVES: In recent years, methodologies used in outcomes research have ad-
vanced. In a field where many researchers from a variety of disciplines (e.g., clini-
cians, epidemiologists, economists, statisticians) interact frequently, a tool to com-
municate information clearly and effectively through graphical means has become
necessary. We present treatment patterns among Veterans Health Administration
(VHA) patients diagnosed with ankylosing spondylitis (AS) using data visualization
techniques.METHODS:Using the VHA Medical SAS® Dataset, we selected patients
18 with at least one AS diagnosis. We identified patients who initiated therapy
with tumor necrosis factor (TNF) and non-TNF agents. For 2 years after the initia-
tion date, we analyzed switches to another TNF, a non-TNF, and continuation and
discontinuation treatment patterns. Using a processing language, we created a
data visualization tool to demonstrate changes in treatment patterns after the first
and second switches. RESULTS: A total of 1,021 AS patients initiated therapy with
TNF. 13.52% of these patients switched to another TNF, 0.20% switched to a non-
TNF, 49.56% discontinued therapy and 36.73% continued their initial therapy.
Among patients who switched to another TNF, 60.87% remained on the switched
therapy, while 31.16% discontinued therapy, 7.97% switched to another TNF, and
no patients switched to a non-TNF. 81.82% of patients who made a second switch
to a TNF medication remained on it, while 9.09% discontinued. A total of 84 AS
patients initiated therapy with a non-TNF. 4.76% of these patients switched to a
TNF, 1.19% switched to another non-TNF, 93.61% discontinued therapy and no
patients continued. Of those patients whose first switch was to a TNF, 50% contin-
ued while the remaining 50% discontinued. No second switches were made.
CONCLUSIONS: Treatment patterns can be difficult to present, especially when
analyzing several years of data and various drug switches. Data visualization tools
can help present these complicated flows effectively to researchers.
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OBJECTIVES: Studies have shown better response for anti-TNFs (aTNF) in combi-
nation with non-biologic DMARDs (nbDMARD), than as monotherapies in rheuma-
toid arthritis (RA) (Nixon 2007). Non-adherence to nbDMARDs prescribed in com-
bination with aTNFs may reduce the benefit of aTNFs. We examined the use of
aTNF monotherapy and adherence with nbDMARDs in RA patients receiving com-
bination aTNFnbDMARDs. METHODS: We conducted claims analysis of adult RA
patients in a US managed care plan, initiating aTNF agents between Jan’06-Dec’10.
aTNF initiators were classified as ‘biologic-naïve’ or ‘previously-exposed’ based on
prior biologic use, and followed until discontinuation of that aTNF or disenroll-
ment. Proportion of patients receiving aTNF as monotherapy (no nbDMARD during
aTNF follow-up) was determined. In combination therapy patients (received nbD-
MARD during aTNF follow-up), adherence to nbDMARDs was defined as the per-
cent of days that patients received any nbDMARD while they were receiving the
aTNF agent. RESULTS: Of 7,074 biologic-naïve RA patients initiating an aTNF, 27%
received it as monotherapy and 73% in combination with nbDMARDs. Of 2,690
aTNF patients previously exposed to biologics, 31% received monotherapy and 69%
in combination with nbDMARDs. Only 42% of patients receiving aTNF mono-
therapy vs. 89% of combination therapy patients had filled a nbDMARD prescrip-
tion during the 6 months prior to initiating the aTNF. Among biologic-naïve com-
bination therapy patients, 52% of patients adhered with nbDMARD therapy less
than 80% of the time while receiving aTNFs; 32% of the patients had less than 60%
adherence. Results were similar for aTNF patients previously exposed to biologics.
CONCLUSIONS:We found that up to 31% of patients receiving an aTNF agent for RA
received it as monotherapy, and a substantial proportion of those receiving com-
bination therapy had less than 60% adherence with nbDMARDs. Some of these
patients may have sub-optimal outcomes, as suggested by evidence that RA pa-
tients receiving aTNFs in combination with nbDMARDs have better response.
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OBJECTIVES: Rheumatoid Arthritis (RA) patients’ access to biologics differs among
European countries. We aimed to explore the views of Portuguese health care
stakeholders on key barriers limiting patients’ access to biologics, areas of inter-
vention to overcome the identified barriers (leverage points) and corresponding
key initiatives. METHODS: A qualitative research consisting of semi-structured
face-to-face interviews with key stakeholders in RA framework. Thirty six people
from eight groups of stakeholders were interviewed: rural and urban general prac-
titioners (GPs), rheumatologists, hospital managers, hospital pharmacists, budget
holders, representatives from rheumatology society and RA patient association.
Interviews were conducted between May and June 2011. Conventional content
analysis with research triangulation was used. RESULTS: The identified key barri-
ers were related with accessibility to primary health care, difficulties in RA diag-
nosis among GPs, inefficient referral to secondary health care, controlled process of
biologics prescription and medical apprehensiveness about biologics safety. The
leverage points included the improvement of national epidemiologic and clinical
knowledge on RA, promotion of disease understanding among patients and GPs,
promotion of biologics benefits among budget holders and overall spreading of the
current treatment guidelines. In order to address the leverage points, the following
key initiatives were selected: optimization of RA national registry; dissemination of
rheumatic symptoms knowledge among patients; increased interaction between
rheumatologists and GPs through clinical sessions; awareness regarding success-
ful case reports about biologics; broader utilization of disease diagnosis and mon-
itoring tool (e.g.DAS28) and implementation of hospital–based research to collect
real-world data. CONCLUSIONS: Most of the key barriers limiting access to biolog-
ics in RA in Portugal are upstream to rheumatology practice. Our findings suggest
that actions should be focused at the primary care level to improve referral to
rheumatologists. In addition, the collection of real-world data seems essential to
characterize RA population, to improve the disease management and to increase
the compliance with current treatment guidelines.
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OBJECTIVES: To compare health care utilization between duloxetine initiators and
pregabalin initiators among fibromyalgia patients in a real-world setting.
METHODS: A retrospective cohort study was conducted based on a US national
commercial health claims database (2006-2009). Fibromyalgia patients who initi-
ated duloxetine or pregabalin in 2008, age 18 to 64, and maintained continuous
health insurance coverage one year before and one year after initiation were as-
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